NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
NervGen will restate its 2025 annual and June 2026 interim financial statements for non-cash accounting adjustments. The filing change introduces reporting uncertainty for a late-stage biotech whose valuation depends heavily on clinical and financing milestones.
NervGen said on Sept. 25 that it will restate its audited financial statements for the year ended Dec. 31, 2025, and its unaudited interim statements for the quarter ended June 30, 2026. The company described the changes as non-cash accounting adjustments.
The restatement reaches both the most recent annual accounts and the latest interim reporting, rather than a single historical period. No further details on the adjustments or their effect on the statements are established here.
NervGen is developing neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. The accounting change therefore sits alongside a late-stage clinical program, where future value is tied to development progress and the ability to fund operations.
The size and direction of the revisions, the accounting items involved and the timing of amended filings remain open questions. Investors will need the restated statements and the company's explanation of the adjustments to determine whether the change affects reported assets, liabilities, expenses or other measures.
NervGen (NGEN) will restate 2025 annual and June 2026 interim financial statements for non-cash accounting adjustments.
The immediate consequence is reporting uncertainty rather than a stated cash impact, and the absence of detail on the adjustments prevents a defensible directional equity call. The restated annual and interim accounts will determine whether the issue is confined to presentation or changes the financial picture supporting NervGen's late-stage development program.
The read is invalidated if the restated statements show only immaterial presentation changes with no effect on key financial measures.
CoverageSource: GlobeNewswire · Published here FRI, SEP 25 · 4:30 PM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
The company describes the adjustments as non-cash, so the restatement may leave liquidity and the clinical program's operating path unchanged.
The restatement covers both the 2025 annual accounts and June 2026 interim statements, leaving the scope and effect of the accounting changes unresolved until amended filings appear.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →